StockNews.AI
PTCT
StockNews.AI
105 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

1. PTC Therapeutics faces securities fraud investigation by Pomerantz LLP. 2. PTC's stock fell 18.62% on disappointing Phase 2 study results. 3. Analysts believe a Phase 3 study is needed for treatment efficacy. 4. The investigation may affect investor confidence in PTC's leadership.

5m saved
Insight
Article

FAQ

Why Bearish?

The significant stock price drop indicates strong negative market sentiment and potential mistrust.

How important is it?

The investigation directly impacts investor sentiment and governance perception, critical for PTCT's future.

Why Short Term?

Immediate investor confidence issues may persist until the investigation concludes or clarifies.

Related Companies

VRTXIONSBMRN
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.   The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 5, 2025, PTC issued a press release "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients."  Although "[t]he study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p<0.0001) at Week 12 and favorable safety and tolerability", analysts who reviewed the data anticipated that the Company would likely need to conduct a Phase 3 study to better establish whether the treatment is actually slowing HD.  On this news, PTC's stock price fell $9.30 per share, or 18.62%, to close at $40.65 per share on May 5, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News